Adrenocortical Carcinoma

Surgical Oncology Clinics of North America

Volumn 15, Issue 3, 2006, Pages 535-553

  Rodgers, Steven E ^a   Evans, Douglas B ^a   Lee, Jeffrey E ^a   Perrier, Nancy D ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6BETA IODOMETHYL 19 NORCHOLEST 5(10) EN 3BETA OL I 131; AMINOGLUTETHIMIDE; CISPLATIN; CORTICOTROPIN; DEXAMETHASONE; DOXORUBICIN; ETOMIDATE; ETOPOSIDE; FLUDROCORTISONE; GOSSYPOL; HYDROCORTISONE; KETOCONAZOLE; METYRAPONE; MITOTANE; SOMATOMEDIN B; SURAMIN;

ADRENAL CORTEX CARCINOMA; ADRENAL INSUFFICIENCY; ADRENALECTOMY; ASPIRATION BIOPSY; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RISK; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONGENITAL ADRENAL HYPERPLASIA; CUSHING DISEASE; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DIZZINESS; DRUG EFFECT; DRUG ERUPTION; DRUG INDUCED HEADACHE; ECTOPIC CORTICOTROPIN PRODUCTION; EMBRYO DEVELOPMENT; FAMILIAL CANCER; FATIGUE; GENE LOCUS; GENE MUTATION; GENETIC RISK; HIGH RISK PATIENT; HIRSUTISM; HISTOPATHOLOGY; HUMAN; HYPERCORTISOLISM; HYPOTHYROIDISM; LAPAROSCOPIC SURGERY; LIVER METASTASIS; LIVER TOXICITY; LUNG METASTASIS; LYMPH NODE METASTASIS; MOOD CHANGE; MYALGIA; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY; PRURITUS; RADIODIAGNOSIS; REVIEW; SCINTIGRAPHY; SIDE EFFECT; SOMNOLENCE; SURVIVAL RATE; SURVIVAL TIME; VISUAL DISORDER;

ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; BECKWITH-WIEDEMANN SYNDROME; BIOPSY, NEEDLE; HUMANS; HYDROCORTISONE; MAGNETIC RESONANCE IMAGING; NEOPLASM STAGING; PROTEINS;

EID: 33746378196     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soc.2006.05.005     Document Type: Review

References (85)

1. Brennan M.F. Adrenocortical carcinoma. CA Cancer J Clin 37 (1987) 348-365
2. National Cancer Institute. Third national cancer survey: incidence data. Natl Cancer Inst Monogr 41 (1975) 1-454
3. Crucitti F., Bellantone R., Ferrante A., et al. The Italian Registry for Adrenal Cortical Carcinoma: analysis of a multiinstitutional series of 129 patients. The ACC Italian Registry Study Group. Surgery 119 (1996) 161-170
4. Icard P., Goudet P., Charpenay C., et al. Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. World J Surg 25 (2001) 891-897
5. Schulick R.D., and Brennan M.F. Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma. Ann Surg Oncol 6 (1999) 719-726
6. Venkatesh S., Hickey R.C., Sellin R.V., et al. Adrenal cortical carcinoma. Cancer 64 (1989) 765-769
7. Wajchenberg B.L., Albergaria Pereira M.A., Medonca B.B., et al. Adrenocortical carcinoma: clinical and laboratory observations. Cancer 88 (2000) 711-736
8. Hsing A.W., Nam J.M., Co Chien H.T., et al. Risk factors for adrenal cancer: an exploratory study. Int J Cancer 65 (1996) 432-436
9. van Seters A.P., van Aalderen W., Moolenaar A.J., et al. Adrenocortical tumour in untreated congenital adrenocortical hyperplasia associated with inadequate ACTH suppressibility. Clin Endocrinol (Oxf) 14 (1981) 325-334
10. Pang S., Becker D., Cotelingam J., et al. Adrenocortical tumor in a patient with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Pediatrics 68 (1981) 242-246
11. Wu S.D. Carcinoma of Adrenal Cortex. Chin Med J (Engl) Suppl 3 (1940) 52-93
12. Macfarlane D.A. Cancer of the adrenal cortex; the natural history, prognosis and treatment in a study of fifty-five cases. Ann R Coll Surg Engl 23 (1958) 155-186
13. Latronico A.C., and Chrousos G.P. Extensive personal experience: adrenocortical tumors. J Clin Endocrinol Metab 82 (1997) 1317-1324
14. Dunton R.F., and Deckers P.J. Estrogen producing adrenocortical carcinoma in an adult male. Contemp Surg 30 (1987) 63-67
15. Allolio B., Hahner S., Weismann D., et al. Management of adrenocortical carcinoma. Clin Endocrinol (Oxf) 60 (2004) 273-287
16. Kendrick M.L., Curlee K., Lloyd R., et al. Aldosterone-secreting adrenocortical carcinomas are associated with unique operative risks and outcomes. Surgery 132 (2002) 1008-1011
17. Stewart P.M., Walker B.R., Holder G., et al. 11 beta-Hydroxysteroid dehydrogenase activity in Cushing's syndrome: explaining the mineralocorticoid excess state of the ectopic adrenocorticotropin syndrome. J Clin Endocrinol Metab 80 (1995) 3617-3620
18. Ribeiro R.C., Sandrini Neto R.S., Schell M.J., et al. Adrenocortical carcinoma in children: a study of 40 cases. J Clin Oncol 8 (1990) 67-74
19. Luton J.P., Cerdas S., Billaud L., et al. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med 322 (1990) 1195-1201
20. Hutter Jr. A.M., and Kayhoe D.E. Adrenal cortical carcinoma. Results of treatment with o,p'DDD in 138 patients. Am J Med 41 (1966) 581-592
21. Icard P., Chapuis Y., Andreassian B., et al. Adrenocortical carcinoma in surgically treated patients: a retrospective study on 156 cases by the French Association of Endocrine Surgery. Surgery 112 (1992) 972-979
22. Humphrey G.B., Pysher T., Holcombe J., et al. Overview on the management of adrenocortical Carcinoma (ACC). Cancer Treat Res 17 (1983) 349-358
23. Barnett Jr. C.C., Varma D.G., El-Naggar A.K., et al. Limitations of size as a criterion in the evaluation of adrenal tumors. Surgery 128 (2000) 973-982
24. Koch C.A., Pacak K., and Chrousos G.P. The molecular pathogenesis of hereditary and sporadic adrenocortical and adrenomedullary tumors. J Clin Endocrinol Metab 87 (2002) 5367-5384
25. Beuschlein F., Reincke M., Karl M., et al. Clonal composition of human adrenocortical neoplasms. Cancer Res 54 (1994) 4927-4932
26. Sameshima Y., Tsunematsu Y., Watanabe S., et al. Detection of novel germ-line p53 mutations in diverse-cancer-prone families identified by selecting patients with childhood adrenocortical carcinoma. J Natl Cancer Inst 84 (1992) 703-707
27. Malkin D., Li F.P., Strong L.C., et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250 (1990) 1233-1238
28. Reincke M., Karl M., Travis W.H., et al. p53 mutations in human adrenocortical neoplasms: immunohistochemical and molecular studies. J Clin Endocrinol Metab 78 (1994) 790-794
29. Wagner J., Portwine C., Rabin K., et al. High frequency of germline p53 mutations in childhood adrenocortical cancer. J Natl Cancer Inst 86 (1994) 1707-1710
30. Gicquel C., Bertagna X., Schneid H., et al. Rearrangements at the 11p15 locus and overexpression of insulin-like growth factor-II gene in sporadic adrenocortical tumors. J Clin Endocrinol Metab 78 (1994) 1444-1453
31. Weber M.M., Fottner C., and Wolf E. The role of the insulin-like growth factor system in adrenocortical tumourigenesis. Eur J Clin Invest 30 Suppl 3 (2000) 69-75
32. Ilvesmaki V., Kahri A.I., Miettinen P.J., et al. Insulin-like growth factors (IGFs) and their receptors in adrenal tumors: high IGF-II expression in functional adrenocortical carcinomas. J Clin Endocrinol Metab 77 (1993) 852-858
33. Zwermann O., Schulte D.M., Reincke M., et al. ACTH 1-24 inhibits proliferation of adrenocortical tumors in vivo. Eur J Endocrinol 153 (2005) 435-444
34. Reincke M., Mora P., Beuschlein F., et al. Deletion of the adrenocorticotropin receptor gene in human adrenocortical tumors: implications for tumorigenesis. J Clin Endocrinol Metab 82 (1997) 3054-3058
35. Skogseid B., Larsson C., Lindgren P.G., et al. Clinical and genetic features of adrenocortical lesions in multiple endocrine neoplasia type 1. J Clin Endocrinol Metab 75 (1992) 76-81
36. Schussheim D.H., Skarulis M.C., Agarwal S.K., et al. Multiple endocrine neoplasia type 1: new clinical and basic findings. Trends Endocrinol Metab 12 (2001) 173-178
37. Langer P., Cupisti K., Bartsch D.K., et al. Adrenal involvement in multiple endocrine neoplasia type 1. World J Surg 26 (2002) 891-896
38. Lenders J.W., Pacak K., Walther M.M., et al. Biochemical diagnosis of pheochromocytoma: which test is best?. JAMA 287 (2002) 1427-1434
39. Nwariaku F.E., Champine J., Kim L.T., et al. Radiologic characterization of adrenal masses: the role of computed tomography-derived attenuation values. Surgery 130 (2001) 1068-1071
40. Peppercorn P.D., and Reznek R.H. State-of-the-art CT and MRI of the adrenal gland. Eur Radiol 7 (1997) 822-836
41. Copeland P.M. The incidentally discovered adrenal mass. Ann Intern Med 98 (1983) 940-945
42. Grumbach M.M., Biller B.M., Braunstein G.D., et al. Management of the clinically inapparent adrenal mass ("incidentaloma"). Ann Intern Med 138 (2003) 424-429
43. Dackiw A.P., Lee J.E., Gagel R.F., et al. Adrenal cortical carcinoma. World J Surg 25 (2001) 914-926
44. Sullivan M., Boileau M., and Hodges C.V. Adrenal cortical carcinoma. J Urol 120 (1978) 660-665
45. Lee J.E., Berger D.H., el-Naggar A.K., et al. Surgical management, DNA content, and patient survival in adrenal cortical carcinoma. Surgery 118 (1995) 1090-1098
46. Weiss L.M. Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. Am J Surg Pathol 8 (1984) 163-169
47. Hough A.J., Hollifield J.W., Page D.L., et al. Prognostic factors in adrenal cortical tumors. A mathematical analysis of clinical and morphologic data. Am J Clin Pathol 72 (1979) 390-399
48. van Slooten H., Schaberg A., Smeenk D., et al. Morphologic characteristics of benign and malignant adrenocortical tumors. Cancer 55 (1985) 766-773
49. Wachenfeld C., Beuschlein F., Zwermann O., et al. Discerning malignancy in adrenocortical tumors: are molecular markers useful?. Eur J Endocrinol 145 (2001) 335-341
50. Schröder S., Niendorf A., Achilles E., et al. Immunocytochemical differential diagnosis of adrenocortical neoplasms using the monoclonal antibody D11. Virchows Arch A Pathol Anat Histopathol 417 (1990) 89-96
51. Tartour E., Caillou B., Tenenbaum F., et al. Immunohistochemical study of adrenocortical carcinoma. Predictive value of the D11 monoclonal antibody. Cancer 72 (1993) 3296-3303
52. Velazquez-Fernandez D., Laurell C., Geli J., et al. Expression profiling of adrenocortical neoplasms suggests a molecular signature of malignancy. Surgery 138 (2005) 1087-1094
53. Wooten M.D., and King D.K. Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature. Cancer 72 (1993) 3145-3155
54. Chiche L., Dousset B., Kieffer E., et al. Adrenocortical carcinoma extending into the inferior vena cava: presentation of a 15-patient series and review of the literature. Surgery 139 (2006) 15-27
55. Gonzalez R.J., Shapiro S., Sarlis N., et al. Laparoscopic resection of adrenal cortical carcinoma: a cautionary note. Surgery 138 (2005) 1078-1085
56. Wood B.J., Abraham J., Hvizda J.L., et al. Radiofrequency ablation of adrenal tumors and adrenocortical carcinoma metastases. Cancer 97 (2003) 554-560
57. Bergenstal D., Hertz R., Lipsett M.B., et al. Chemotherapy of adrenocortical cancer with O,P'-DDD. Ann Intern Med 53 (1960) 672-682
58. Lubitz J.A., Freeman L., and Okun R. Mitotane use in inoperable adrenal cortical carcinoma. JAMA 223 (1973) 1109-1112
59. Henley D.J., van Heerden J.A., Grant C.S., et al. Adrenal cortical carcinoma-a continuing challenge. Surgery 94 (1983) 926-931
60. Karakousis C.P., Rao U., and Moore R. Adrenal adenocarcinomas: histologic grading and survival. J Surg Oncol 29 (1985) 105-111
61. Haak H.R., Hermans J., van de Velde C.J., et al. Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. Br J Cancer 69 (1994) 947-951
62. van Slooten H., Moolenaar A.J., van Seters A.P., et al. The treatment of adrenocortical carcinoma with o,p'-DDD: prognostic implications of serum level monitoring. Eur J Cancer Clin Oncol 20 (1984) 47-53
63. Markoe A.M., Serber W., Micaily B., et al. Radiation therapy for adjunctive treatment of adrenal cortical carcinoma. Am J Clin Oncol 14 (1991) 170-174
64. Vassilopoulou-Sellin R., Guinee V.F., Klein M.J., et al. Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer. Cancer 71 (1993) 3119-3123
65. Bodie B., Novick A.C., Pontes J.E., et al. The Cleveland Clinic experience with adrenal cortical carcinoma. J Urol 141 (1989) 257-260
66. Baudin E., Pellegriti G., Bonnay M., et al. Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p'DDD) levels on the treatment of patients with adrenocortical carcinoma. Cancer 92 (2001) 1385-1392
67. Haq M.M., Legha S.S., Samaan N.A., et al. Cytotoxic chemotherapy in adrenal cortical carcinoma. Cancer Treat Rep 64 (1980) 909-913
68. Decker R.A., Elson P., Hogan T.F., et al. Eastern Cooperative Oncology Group study 1879: mitotane and adriamycin in patients with advanced adrenocortical carcinoma. Surgery 110 (1991) 1006-1013
69. Flynn S.D., Murren J.R., Kirby W.M., et al. P-glycoprotein expression and multidrug resistance in adrenocortical carcinoma. Surgery 112 (1992) 981-986
70. Haak H.R., van Seters A.P., Moolenaar A.J., et al. Expression of P-glycoprotein in relation to clinical manifestation, treatment and prognosis of adrenocortical cancer. Eur J Cancer 29A (1993) 1036-1038
71. Bates S.E., Shieh C.Y., Mickley L.A., et al. Mitotane enhances cytotoxicity of chemotherapy in cell lines expressing a multidrug resistance gene (mdr-1/P-glycoprotein) which is also expressed by adrenocortical carcinomas. J Clin Endocrinol Metab 73 (1991) 18-29
72. Berruti A., Terzolo M., Sperone P., et al. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocr Relat Cancer 12 (2005) 657-666
73. Allolio B., Jaursch-Hancke C., Reincke M., et al. [Treatment of metastatic adrenal carcinoma with suramin]. Dtsch Med Wochenschr 114 (1989) 381-384 [in German]
74. Miglietta L., Barreca A., Repetto L., et al. Suramin and serum insulin-like growth factor levels in metastatic cancer patients. Anticancer Res 13 (1993) 2473-2476
75. Arlt W., Reincke M., Siekmann L., et al. Suramin in adrenocortical cancer: limited efficacy and serious toxicity. Clin Endocrinol (Oxf) 41 (1994) 299-307
76. Wu Y.W., Chik C.L., and Knazek R.A. An in vitro and in vivo study of antitumor effects of gossypol on human SW-13 adrenocortical carcinoma. Cancer Res 49 (1989) 3754-3758
77. Flack M.R., Pyle R.G., Mullen N.M., et al. Oral gossypol in the treatment of metastatic adrenal cancer. J Clin Endocrinol Metab 76 (1993) 1019-1024
78. Allolio B., Schulte H.M., Kaulen D., et al. Nonhypnotic low-dose etomidate for rapid correction of hypercortisolaemia in Cushing's syndrome. Klin Wochenschr 66 (1988) 361-364
79. Thoren M., Adamson U., and Sjoberg H.E. Aminoglutethimide and metyrapone in the management of Cushing's syndrome. Acta Endocrinol (Copenh) 109 (1985) 451-457
80. Verhelst J.A., Trainer P.J., Howlett T.A., et al. Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome. Clin Endocrinol (Oxf) 35 (1991) 169-178
81. Contreras P., Rojas A., Biagini L., et al. Regression of metastatic adrenal carcinoma during palliative ketoconazole treatment. Lancet 2 (1985) 151-152
82. Sinnaeve L.J., and Becks G.P. Preoperative ketoconazole therapy for adrenocortical carcinoma. CMAJ 141 (1989) 131-133
83. Sonino N., Boscaro M., Paoletta A., et al. Ketoconazole treatment in Cushing's syndrome: experience in 34 patients. Clin Endocrinol (Oxf) 35 (1991) 347-352
84. Engelhardt D., Jacob K., and Doerr H.G. Different therapeutic efficacy of ketoconazole in patients with Cushing's syndrome. Klin Wochenschr 67 (1989) 241-247
85. Engelhardt D., and Weber M.M. Therapy of Cushing's syndrome with steroid biosynthesis inhibitors. J Steroid Biochem Mol Biol 49 (1994) 261-267